BioSpace News Archive

Olympus announced today the results of a pilot study showing the safety and effectiveness of the ViziShot 2 FLEX 19 G EBUS-TBNA Needle in gathering tissue samples critical to guiding treatment of non-small cell lung cancer (NSCLC).

XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s Special Meeting of Shareholders.

Renovacor, Inc. announced the closing of its previously announced business combination with Chardan Healthcare Acquisition 2 Corp., a special purpose acquisition company sponsored by Chardan Capital Markets.

Terns Pharmaceuticals, Inc. announced that the Company’s management team will present at the following upcoming investor conferences in September.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced that the Company will present at the following upcoming investor conferences.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences.

Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September.

Nyxoah SA announced that Olivier Taelman, Chief Executive Officer, and Fabian Suarez, Chief Financial Officer, will participate at the Baird 2021 Global Healthcare Conference on Tuesday, September 14, 2021, with a virtual presentation at 3:05 pm CET / 9:05 am ET.